相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma
Heinz Ludwig et al.
BLOOD (2009)
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
Stefan Knop et al.
BLOOD (2009)
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program
Joseph R. Mikhael et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
A. Dispenzieri et al.
LEUKEMIA (2009)
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
R. A. Kyle et al.
LEUKEMIA (2009)
Myeloma Bone Disease: Recent Advances in Biology, Diagnosis, and Treatment
Orhan Sezer
ONCOLOGIST (2009)
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma
A. Palumbo et al.
ANNALS OF ONCOLOGY (2008)
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
Michael Wang et al.
BLOOD (2008)
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
Antonio Palumbo et al.
BLOOD (2008)
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature
Andreas A. Argyriou et al.
BLOOD (2008)
The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma
Stefania Ciolli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma
Donna E. Reece et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma
S. Vincent Rajkumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group consensus statement
M. A. Hussein et al.
LEUKEMIA (2008)
Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma
C. Jakob et al.
LEUKEMIA (2008)
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis
E. Terpos et al.
LEUKEMIA (2008)
Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system
C. L. H. Snozek et al.
LEUKEMIA (2008)
VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma
M. Pineda-Roman et al.
LEUKEMIA (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
被撤回的出版物: Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma:: results of a multicenter randomized clinical trial (Retracted article. See vol. 113, pg. 6265, 2009)
Abderrahman Abdelkefi et al.
BLOOD (2008)
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
A. Palumbo et al.
LEUKEMIA (2008)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Meletios Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
Donna M. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Extended follow-up of a phase 3 trial in relapsed multiple myeloma:: final time-to-event results of the APEX trial
Paul G. Richardson et al.
BLOOD (2007)
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
Thierry Facon et al.
LANCET (2007)
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma:: A report from the GIMEMA -: Italian multiple myeloma network
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma:: Combination therapy improves time to progression
Robert Z. Orlowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma
Martin Kropff et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD)
Faith E. Davies et al.
HAEMATOLOGICA (2007)
Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM)
P. Sonneveld et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients
Gareth J. Morgan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy
R. Baz et al.
ANNALS OF ONCOLOGY (2006)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma
Mohamad A. Hussein et al.
MAYO CLINIC PROCEEDINGS (2006)
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled-trial
A Palumbo et al.
LANCET (2006)
Guidelines on the diagnosis and management of multiple myeloma 2005
A Smith et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma
GW Dewald et al.
BLOOD (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma
C Kyriakou et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma
R García-Sanz et al.
LEUKEMIA (2004)
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial
A Palumbo et al.
BLOOD (2004)
Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma
MA Dimopoulos et al.
HEMATOLOGY JOURNAL (2004)
Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma
MH Kropff et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Serum test for assessment of patients with Bence Jones myeloma
AR Bradwell et al.
LANCET (2003)
Thalidomide and dexamethasone combination for refractory multiple myeloma
MA Dimopoulos et al.
ANNALS OF ONCOLOGY (2001)
Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma
M Drayson et al.
BLOOD (2001)